AltStreet
EDGAR Verified
Primary Source · SEC.gov

Verdad Biotech Fund, L.P.

CIK 0002139106Fund Vehicle2026 vintage506(b), 506(c), Rule 504, 4(a)(5)

Raised

Pre-open

Investors

—

Min Invest

$0

AltStreet Analysis

·

Generated from EDGAR primary sources

Verdad Biotech Fund, L.P. is a longevity biotech-focused investment vehicle filed June 9, 2026, in pre-open status with no capital raised or investor count disclosed. The filing claims exemptions under Rule 506(b), 506(c), Rule 504, and Section 4(a)(5). Minimum investment was not disclosed on the filing.

This longevity biotech vehicle files under multiple overlapping exemptions (506(b), 506(c), Rule 504, and 4(a)(5)), an unusual combination that may indicate structural complexity or uncertainty about the final distribution strategy. Pre-open filings in specialized biotech strategies typically target institutional or high-net-worth investors with six- or seven-figure minimums, though none is specified here.

Data Flags

exemptionsFiling claims four separate exemptions simultaneously (506(b), 506(c), Rule 504, 4(a)(5)), an uncommon combination that suggests either multi-stage capital structure or filing uncertainty
generalPre-open filing with no first sale date, total amount sold, or investor count disclosed; minimal operational transparency at time of filing
industry_groupIndustry group, securities type, and state of incorporation all left unspecified despite required fields on Form D

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002139106
Entity NameVerdad Biotech Fund, L.P.
Exemption506(b), 506(c), Rule 504, 4(a)(5)
First Sale Date—
Filing DateJune 9, 2026
Accession Number0002139106-26-000001
Total Amount Sold—
Total Investors—
Minimum Investment$0 (no stated minimum)
Securities Type—
State of IncorporationNot specified
Amendment CountOriginal filing only

Is this your offering?

Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.

Claim Profile — FreeGet Verified — $2,400/yr

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.